Login / Signup

Real-World Data (RWD) on the 3-Year Follow-Up Outcomes of Different CNS Prophylaxis Strategies Across CNS-IPI Risk Groups in Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma.

Anadil FaqahSummaiya AsifSuleyman Yasin GoksuHassan S Sheikh
Published in: JCO global oncology (2021)
Our study while did not find statistical significance did indicate a lower incidence of CNS relapse with the addition of systemic HD MTX to IT MTX in the high-risk DLBCL population.
Keyphrases
  • blood brain barrier
  • risk factors
  • diffuse large b cell lymphoma
  • electronic health record
  • low grade
  • metabolic syndrome
  • type diabetes
  • free survival